BioCentury | Feb 6, 2006
Product Development

Breathless opportunities

...encodes a multidomain serine protease inhibitor that is thought to be active against multiple substrates. ADAM33...
BioCentury | Jul 15, 2002
Company News

Genome Therapeutics, Schering-Plough other research news

...Researchers published in Nature evidence that ADAM33 is involved in the etiology of asthma. Genome-wide analysis...
...and asthma and bronchial hyper-responsiveness. Haplotype analysis of 135 polymorphisms in 23 genes showed that ADAM33...
...metalloproteases. Genome Therapeutics Corp. (GENE), Waltham, Mass. Schering-Plough Corp. (SGP), Kenilworth, N.J., et al. Product: ADAM33...
Items per page:
1 - 2 of 2